Shogo Takei
Overview
Explore the profile of Shogo Takei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
90
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsuge A, Watanabe S, Kawazoe A, Togashi Y, Itahashi K, Masuda M, et al.
Cancer Immunol Res
. 2024 Nov;
13(2):273-285.
PMID: 39602577
Regulatory T (Treg) cells play key roles in cancer immunity by suppressing a range of antitumor immune responses and contributing to resistance to PD-1 blockade therapy. Given their critical roles...
2.
Takei S, Tanaka Y, Lin Y, Koyama S, Fukuoka S, Hara H, et al.
J Immunother Cancer
. 2024 Feb;
12(2).
PMID: 38336371
Background: Immune checkpoint inhibitor (ICI) combinations represent an emerging treatment strategies in cancer. However, their efficacy in microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal cancer (CRC) is variable. Here,...
3.
Sakai J, Watanabe J, Ohya H, Takei S, Toritani K, Suwa Y, et al.
Int J Colorectal Dis
. 2023 May;
38(1):145.
PMID: 37243791
Purpose: Reports of redo laparoscopic colorectal resection (Re-LCRR) are scarce. In order to evaluate the safety and short-term outcomes of Re-LCRR, we performed a matched case-control analysis of patients who...
4.
Takei S, Kawazoe A, Shitara K
Cancers (Basel)
. 2022 Feb;
14(4).
PMID: 35205802
Immune checkpoint inhibitors (ICIs) such as anti-programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) monoclonal antibodies have prolonged survival in various types of malignancies, including advanced gastric cancer...
5.
Watanabe J, Ishibe A, Takei S, Suwa Y, Suwa H, Ota M, et al.
Dis Colon Rectum
. 2021 Apr;
64(7):e387-e388.
PMID: 33872282
No abstract available.
6.
Takei S, Homma Y, Matsuyama R, Endo I
BMJ Case Rep
. 2021 Feb;
14(2).
PMID: 33547122
We herein report a woman who was suffering from type 1 diabetes and hearing impairment and whose mother had mitochondrial disease. Abdominal ultrasound identified a hepatic tumour, and a further...
7.
Takei S, Watanabe J, Ishibe A, Suwa Y, Nakagawa K, Ozawa M, et al.
Int J Colorectal Dis
. 2021 Feb;
36(6):1323-1328.
PMID: 33528751
Background: Randomized controlled trials (RCTs) comparing intracorporeal anastomosis (IA) and extracorporeal anastomosis (EA) could not prove a significant reduction in postoperative stay and therefore did not provide sufficient evidence of...
8.
Takei S, Ishibe A, Watanabe J, Watanabe K, Suwa Y, Suzuki S, et al.
Int J Colorectal Dis
. 2020 Aug;
35(12):2323-2329.
PMID: 32860080
Purpose: Although the effectiveness of antiemetic therapy for colorectal cancer chemotherapy has improved with further drug development, some patients still suffer from chemotherapy-induced nausea and vomiting (CINV) even with only...
9.
Sahara K, Watanabe J, Ishibe A, Goto K, Takei S, Suwa Y, et al.
Surg Today
. 2020 Jul;
51(2):268-275.
PMID: 32710131
Purpose: The objective of the current study was to assess the therapeutic benefit of lymphadenectomy according to the extent of lymphadenectomy. Methods: Patients undergoing colectomy for right-sided colon cancer were...